Biblio Discovery — Demo Discovery Service

109 hasil

Menampilkan 1–20 · 0,11 detik · RSS

Jurnal

Clinical Hematology International

Scopus

ISSN 2590-0048 · SAABRON PRESS · 109 artikel di indeks

  1. Artikel Jurnal

    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

    Torben Plesner; Simon J. Harrison; Hang Quach dkk.

    Clinical Hematology International, Vol. 5 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Introduction This phase 1 trial assessed the safety, pharmacokinetics, and preliminary antitumor activity of RO7297089, an anti-BCMA/CD16a bispecific antibody. Methods RO7297089 was administered weekly by intravenous infusion to patients with relapsed/refractory multiple myeloma. The…

  2. Artikel Jurnal

    Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)

    Zoe van de Wyngaert; Florent Malard; Cyrille Hulin dkk.

    Clinical Hematology International, Vol. 5 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Introduction Despite the implementation of new therapeutic agents, management of relapsed multiple myeloma (MM) remains a challenge. Salvage autologous hematopoietic cell transplant (AHCT) remains a valid therapeutic option for eligible patients who achieve prolonged response after a first…

  3. Artikel Jurnal

    Retrospective Multicenter Real-Life Study on the First-Line Treatment of Classical Hodgkin Lymphoma in Argentina

    Carolina Mahuad; Otero Victoria; Korin Laura dkk.

    Clinical Hematology International, Vol. 4 No. 1-2 · 2022 · Inggris · DOAJ Scopus

    Abstract There are no data in Argentina on the response rates to first-line treatment of classical Hodgkin Lymphoma (cHL) outside clinical trials. A total of 498 patients from 7 public and private hospitals in Argentina were retrospectively examined. The median follow-up was 37.4 months (CI 95%…

  4. Artikel Jurnal

    Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

    Ali Ibrahim; Nour Moukalled; Rami Mahfouz dkk.

    Clinical Hematology International, Vol. 4 No. 1-2 · 2022 · Inggris · DOAJ Scopus

    Abstract The treatment of newly diagnosed chronic phase chronic myeloid leukemia (CML) with nilotinib has resulted in a higher rate of major molecular (MMR) and complete cytogenetic response (CCyR) at 12 months compared to imatinib but at a higher cumulative cost and increased risk of serious…

  5. Artikel Jurnal

    Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas

    Ibrahim N. Muhsen; Riad El Fakih; Mehdi Hamadani dkk.

    Clinical Hematology International, Vol. 4 No. 1-2 · 2022 · Inggris · DOAJ Scopus

    Abstract Primary cutaneous γδ T-cell lymphoma (PCGDTL) is a rare subtype of non-Hodgkin lymphoma (NHL) that arises from T-cells with γδ T-cell receptors. The exact incidence of PCGDTL is unknown, as it is usually lumped with other cutaneous lymphomas, which are also uncommon. It is one of the…

  6. Artikel Jurnal

    The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities

    Rose Ellard; Michelle Kenyon; Daphna Hutt dkk.

    Clinical Hematology International, Vol. 4 No. 3 · 2022 · Inggris · DOAJ Scopus

    Abstract Chimeric antigen receptor T-cell (CAR T) therapy is a new and rapidly developing field. Centers across the world are gaining more experience using these innovative anti-cancer treatments, transitioning from the ‘bench’ to the ‘bedside’, giving benefit to an increasing number of patients…

  7. Artikel Jurnal

    Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?

    Anna Komitopoulou; I. Baltadakis; I. Peristeri dkk.

    Clinical Hematology International, Vol. 4 No. 1-2 · 2022 · Inggris · DOAJ Scopus

    Abstract Long-term disease control is achieved in 80–90% of patients with acute lymphoblastic leukemia of B origin (B-ALL). About half of adult and 10% of pediatric patients develop refractory or relapsed disease, whereas survival after relapse accounts about 10% in adults and 30–50% in children…

  8. Artikel Jurnal

    The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients

    Johnny Zakhour; Fatima Allaw; Sara F. Haddad dkk.

    Clinical Hematology International, Vol. 5 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract With the rising number of patients undergoing hematopoietic stem cell transplantation (HSCT), clinicians are more likely to encounter infectious complications in immunocompromised hosts, particularly cytomegalovirus (CMV) infection. Besides the high mortality of CMV end-organ disease…

  9. Artikel Jurnal

    Organizational Challenges in the Pediatric Onco-hematology Units During the First and Second Wave of the COVID-19 Pandemic: A National Survey in Italy

    Matteo Amicucci; Valentina Biagioli; Elena Rostagno dkk.

    Clinical Hematology International, Vol. 4 No. 3 · 2022 · Inggris · DOAJ Scopus

    Abstract This study aimed to describe and compare, at a national level, the measures implemented in the pediatric onco-hematology units and the number of infections among patients and healthcare staff during the first and second wave of the COVID-19 pandemic in Italy. A multicenter, descriptive…

  10. Artikel Jurnal

    Selected Domains within a Comprehensive Geriatric Assessment in Older Patients with Non-Hodgkin Lymphoma are Highly Associated with Frailty

    María del Pilar Gamarra Samaniego; Carmelo J. Blanquicett; Roger V. Araujo Castillo dkk.

    Clinical Hematology International, Vol. 4 No. 1-2 · 2022 · Inggris · DOAJ Scopus

    Abstract Background The incidence of Non-Hodgkin Lymphoma (NHL) is increasing, particularly among older patients who tend to have worse outcomes and can be predisposed to increased toxicities and less treatment tolerance. Therefore, a thorough pre-treatment assessment is essential. A comprehensive…

  11. Artikel Jurnal

    FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL

    Caroline Dartigeas; Borhane Slama; Margaret Doyle dkk.

    Clinical Hematology International, Vol. 4 No. 3 · 2022 · Inggris · DOAJ Scopus

    Abstract The FIRE study investigated the real-world effectiveness and safety of ibrutinib in prospectively observed patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) in France. Patients were mostly relapsed/refractory with high-risk…

  12. Artikel Jurnal

    The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

    Obada Ababneh; Hassan Abushukair; Aref Qarqash dkk.

    Clinical Hematology International, Vol. 4 No. 1-2 · 2022 · Inggris · DOAJ Scopus

    Abstract The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors are being used and studied to…

  13. Artikel Jurnal

    Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective

    Ahmad Ibrahim; Nabil Chamseddine; Jean El-cheikh dkk.

    Clinical Hematology International, Vol. 4 No. 4 · 2022 · Inggris · DOAJ Scopus

    Abstract Multiple myeloma (MM) is a prevalent hematological malignancy. Resource-constrained settings such as the Middle East are particularly burdened by the increasing trends in MM morbidity and mortality in addition to challenges in the management of MM. It thus becomes necessary to identify and…

  14. Artikel Jurnal

    High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens

    Katrine Fladeland Iversen; Line Nederby; Thomas Lund dkk.

    Clinical Hematology International, Vol. 4 No. 3 · 2022 · Inggris · DOAJ Scopus

    Abstract Multiple myeloma is an incurable disease characterized by unregulated growth of malignant plasma cells in the bone marrow (BM). Tumor-induced dysfunction of T-cells may be responsible for immune evasion and failure of immunotherapy. Therefore, a better understanding of the phenotype of…